IDEAYA Biosciences Inc (NAS:IDYA)

$ 27.77 0.04 (0.14%) Market Cap: 2.40 Bil Enterprise Value: 1.50 Bil PE Ratio: 0 PB Ratio: 2.04 GF Score: 30/100

IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
IDEAYA Biosciences Inc At Barclays Lunchtime Fireside Chat Series Transcript
Dec 05, 2023
IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
IDEAYA Biosciences Inc at Citi Global Technology Conference Transcript
Sep 06, 2023
IDEAYA Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023
IDEAYA Biosciences Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
IDEAYA Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
IDEAYA Biosciences Inc at Guggenheim Healthy Altitudes Summit Transcript
Mar 15, 2023
IDEAYA Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 21, 2023
IDEAYA Biosciences Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023
IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
IDEAYA Biosciences Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
IDEAYA Biosciences Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
IDEAYA Biosciences Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 09, 2022
IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
IDEAYA Biosciences Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020

IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 04:15PM GMT

Release Date Price: $35.89 (-1.89%)

Transcript

Anupam Rama J.P. Morgan Securities LLC;Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama, I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Mary Hall, Priyanka Grover. Our next presenting company is IDEAYA. And presenting on behalf of the company, we have CEO, Yujiro Hata. Yujiro?

Yujiro Hata

IDEAYA Biosciences Inc - President, Chief Executive Officer, Director

Oh great. Well thank you so much, everyone for attending today's presentation, and thank you also for JPMorgan for the opportunity to present today. So earlier on Sunday, we provided several key program updates, which I'll highlight today. In addition, we did give our 2024 corporate guidance.

In 2024 we believe there's going to be a big opportunity for darovasertib. In particular, a significant focus on our Phase 2 company-sponsored neoadjuvant uveal melanoma trial. In addition, we've given specific guidance of our target to present Phase 2 clinical efficacy data in the middle of this year.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.